2015 AACC Annual Meeting: Featured Resources

In addition to numerous presentations and abstracts at the upcoming 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, Mayo Medical Laboratories representatives will also be available at booth #3055 in the exhibit hall to discuss:


Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an inflammatory protein produced in the vascular intima and is highly upregulated in atherosclerotic plaques, especially within the necrotic core and macrophages surrounding vulnerable plaques.

Lp-PLA2 activity testing can be used to identify persons at increased risk for CHD events, obtain a prognostic value independent of standard lipid profile testing, and can be used in conjunction with clinical evaluation and patient risk assessment.



To better accommodate important updates in the screening guidelines for HPV, an infection present in 20 million people in the United States and resulting in 6.2 million new infections per year, Mayo Medical Laboratories now offers testing for the detection of high-risk HPV (hrHPV), with genotyping for HPV-16 and HPV-18.



The new Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered to assess a trough level quantitation for evaluation of patients with loss of response to infliximab.



Alpha-1-antitrypsin (A1A) is a protein that inhibits the enzyme neutrophil elastase. It is predominantly synthesized in the liver and secreted into the bloodstream. The inhibition function is especially important in the lungs because it protects against excess tissue degradation.

Historically, IEF has been the primary method for characterizing variants, though in some cases the interpretation is difficult and prone to error. Serum quantitation is helpful in establishing a diagnosis, but can be influenced by other factors. A proteomic method using trypsin-digested sera can detect the mutated peptides of the S and Z alleles, but can miss disease alleles other than the S and Z alleles. Our testing combines all of these methods to provide a comprehensive result.



Historically, only certain pockets of the United States posed a risk for tick-borne disease. However, the geographic range of ticks has expanded and large areas of the population are now at risk. Because of this increased risk, it is important that physicians recognize who to test, when to test, and what test to use.



Mayo Clinic’s clinical microbiology laboratories span all areas of conventional and molecular microbiology and offer more than 200 tests designed for rapid identification of the causative agents of infectious diseases.

Our laboratories perform over 2.8 million tests annually and have developed and  implemented culture techniques, immunoassays, and molecular methods for rapid detection and identification of microbial pathogens.



Brent Westra

Brent Westra is a Marketing Segment Manager at Mayo Medical Laboratories. He leads marketing strategies for product management and specialty testing along with new media innovations. Brent has worked at Mayo Clinic since 2011.